Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The company also reported significant progress toward its internally defined Sustainable Development Goals
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Subscribe To Our Newsletter & Stay Updated
